◆Ritlecitinib approved for alopecia areata, largest JAK inhibitor trial confirms 80% regrowth◆Stemson Therapeutics completes first human follicle cloning safety study◆Exosome therapy: 18-month follow-up data shows durable results in 62% of patients◆CRISPR-based AGA treatment enters Phase I, first gene-editing approach for hair loss◆Clascoterone Phase 3 results: topical antiandrogen matches finasteride without systemic effects◆Oral minoxidil 1.25mg outperforms topical 5% in new randomised trial◆Wnt pathway activator SM04554 fails Phase III, researchers identify why◆Scalp microbiome transplant: first human results show promise for seborrheic alopecia◆PRP meta-analysis 2025: 28 trials, 1,400 patients, here are the real numbers◆Dutasteride mesotherapy significantly outperforms oral dutasteride in crown hair density◆Ritlecitinib approved for alopecia areata, largest JAK inhibitor trial confirms 80% regrowth◆Stemson Therapeutics completes first human follicle cloning safety study◆Exosome therapy: 18-month follow-up data shows durable results in 62% of patients◆CRISPR-based AGA treatment enters Phase I, first gene-editing approach for hair loss◆Clascoterone Phase 3 results: topical antiandrogen matches finasteride without systemic effects◆Oral minoxidil 1.25mg outperforms topical 5% in new randomised trial◆Wnt pathway activator SM04554 fails Phase III, researchers identify why◆Scalp microbiome transplant: first human results show promise for seborrheic alopecia◆PRP meta-analysis 2025: 28 trials, 1,400 patients, here are the real numbers◆Dutasteride mesotherapy significantly outperforms oral dutasteride in crown hair density
